Home > Insider Trading > Filing (0001493152-22-018553)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1641631	Beyond Air Inc.	XAIR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1426873	Amir Avniel	C/O Beyond Air, Inc., 900 Stewart Avenue, Suite 301 Garden City NY 11530	Coo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-06-30	65,500	$6.50	408,027	No	4	S	Direct
Common Stock	Disposition	2022-06-30	2,600	$6.57	13,733	No	4	S	Indirect	Held by Dandelion Investments Ltd.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	Held by Dandelion Investments Ltd.

Footnotes

The sale was made to satisfy an Israeli tax obligation resulting from the reporting person's ownership of shares of Advanced Inhalation Therapies (AIT) Ltd., an Israeli corporation, which merged with Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.), a Delaware corporation, on January 13, 2017.
The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.47 to $6.59, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.585, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.